Author

G. De Conti

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:perturbation response prediction· 1 Approach:statistical model· 1

Frequent Co-Authors

C. Lieftink· 3 shared R. Bernards· 3 shared A. Velds· 2 shared B. Morris· 2 shared F. Jochems· 2 shared K. Groot· 2 shared L. Wardak· 2 shared R. H. Medema· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Lieftink

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Paradoxical activation of oncogenic signaling as a cancer treatment strategy

M. H. Dias, A. Friskes, S. Wang, J. M. H. Fernandes Neto, F. v. Gemert, S. Mourragui, H. J. Kuiken, S. Mainardi, D. Alvarez-Villanueva, C. Lieftink, B. Morris, A. Dekker, E. v. Dijk, C. Papagianni, M. S. da Silva, , R. Bernards

This study shows that inhibiting PP2A and WEE1 together can kill colon cancer cells by causing DNA replication collapse and cell death, and that resistance to this treatment suppresses tumor growth.

bioRxiv · Feb 6, 2023Cancer Biology

Genetic and compound screens uncover factors modulating cancer cell response to indisulam

Z. Pogacar, K. Groot, F. Jochems, M. Dos Santos Dias, B. Morris, M. Roosen, L. Wardak, G. De Conti, A. Velds, C. Lieftink, R. L. Beijersbergen, R. Bernards, R. Leite de Oliveira

This study identifies genetic and compound factors that modulate cancer cell response to the drug indisulam, revealing therapeutic strategies for its clinical reuse.

bioRxiv · Dec 20, 2021Cancer Biology

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity

Z. Pogacar, J. L. Johnson, L. Krenning, G. De Conti, C. Lieftink, A. Velds, L. Wardak, F. Jochems, K. Groot, A. Schepers, L. Wang, J.-Y. Song, M. van de Ven, O. van Tellingen, R. H. Medema, , R. Leite de Oliveira

The paper identifies that combining indisulam with palbociclib enhances senescence in cancer cells by inhibiting CDK2 kinase activity.

bioRxiv · Oct 18, 2021Cancer Biology